

Fenwal Amicus

Therapeutic apheresis and cell collection

**PRECISION COLLECTION.
SOFT, SAFE CARE.**

The Gentle Science design of Fenwal Amicus puts precision MNC collection at your fingertips—while providing soft, safe care to the patients and donors who count on you.



Putting precision collection at your fingertips


80%
Median
MNC Collection
Efficiency (CE1)

Optimize collection efficiencies

Meeting your patients' clinical needs is always your primary goal. The Fenwal Amicus Gentle Science design delivers precision with the high efficiency you've come to expect.

HIGH COLLECTION EFFICIENCIES

	Auto ^{1*} (mobilized)	Allo ^{1*} (mobilized)	Allo ² (non-mobilized)
MNC CE1 % (median)	80 (n=87)	70 (n=17)	
MNC CE2 % (median)	60 (n=75)		
CD34+ CE1 % (median)	66 (n=85)	82 (n=18)	CD34+ CE1 % (mean ± SD) 64 ± 15 (n=12)



● Platelet ● Red blood cell ● Mononuclear cell ● Granulocyte

Longer MNC harvest can be achieved by increasing the RBC Offset to fully capture the MNCs.

Tailor collections

Every MNC collection is different because every patient and donor is different. Fenwal Amicus is designed to make it easy to tailor collections for high product purity and high MNC yield.

HIGH PRODUCT PURITY


	Auto ^{1*} (mobilized)	Allo ^{1*} (mobilized)	Allo ² (non-mobilized)
Platelets x 10¹¹ (median)	0.43 (n=97)	0.57 (n=18)	Platelets x 10¹¹ (mean ± SD) 0.46 ± 14.7 (n=12)
Granulocytes % (median)	33 (n=97)	14 (n=19)	
Red Cell Hct % (median)	13.6 (n=62)	3.8 (n=14)	Red Cell Hct % (mean ± SD) 9.6 ± 2.6 (n=12)
Product Volume (mL) (median)	176 (n=97)	160 (n=18)	Product Volume (mL) (mean ± SD) 50.4 ± 3.5 (n=12)

* Mobilization with G-CSF + chemotherapy for patients and G-CSF alone for healthy subjects per institutional practice.

Providing soft, safe care to patients and donors

10% Median Platelet Loss

← Platelets return during collection



With Amicus, whole blood enters the centrifuge chamber and begins to separate, as the separation interface is established platelet rich plasma is returned to the patient.

Spare platelets

One therapeutic procedure shouldn't result in the need for another one. The Gentle Science design of Fenwal Amicus keeps median platelet loss at 10%¹, so you can perform MNC procedures on patients and donors with low platelet counts, with reduced risk of an associated platelet transfusion.

LOW PLATELET LOSS

	Auto ¹ (mobilized)	Allo ¹ (mobilized)		Allo ² (non-mobilized)
Platelet loss %	10	7	Platelet loss %	2.3 ± 4.7
(median)	(n=95)	(n=18)	(mean ± SD)	(n=12)
Platelet CE1 %	4	4	Platelet CE1 %	3.6 ± 1.3
(median)	(n=94)	(n=19)	(mean ± SD)	(n=12)

163mL Extracorporeal Kit Volume

Support patient comfort

Comfort is a key part of the care you provide. With low extracorporeal volume (ECV) and low-noise operation, Fenwal Amicus delivers a gentle experience—even for delicate patients and donors—while sterilization of apheresis kits using irradiation avoids the risk of reactions related to patient and donor exposure to residual ethylene oxide.

Source

¹ FCRP-0297: Investigational Plan for the Harvesting of PBSC in G-CSF and Chemotherapy Mobilized Patients using the Amicus Separator, December, 2000 and Post Hoc Analysis for FCRP-0297, March, 2014. Data on file.

² Steininger PA, Strasser EF, Weiss D, Achenbach S, Zimmerman R, Ekstein R. First comparative evaluation of a new leukapheresis technology in non-cytokine-stimulated donors. Vox Sanguinis 2013; DOI 10.1111/vox. 12102

Fresenius Kabi USA

Three Corporate Drive
Lake Zurich, Illinois 60047
847 550 2300
888 391 6300
www.fresenius-kabi.us/gentlescience

INFUSE ~ TRANSFUSE ~ NOURISH

